93P: Chemoradiotherapy with radical intent for small cell lung cancer (SCLC): A 5 year retrospective review

Abstract

Background: Optimal therapy for radically treated SCLC is concurrent hyperfractionated chemoradiotherapy (CCRT-45 Gy/30fractions/3 weeks, 3-D conformal) and prophylactic cranial irradiation (after complete or a good partial response). CCRT is not always feasible; patients may then have sequential chemoradiotherapy (SCRT)-45 Gy/15 fractions/3 weeks, 2D or 3D planned. Methods: CCRT and 3D planning were introduced locally in 2010. We reviewed all SCLC cases treated with both chemotherapy (CT) and radiotherapy (RT) with potentially curative intent between 2010 and 2014 at Velindre Cancer Centre. Results: 87 patients were treated. 86 received both CT and RT (73 sequential and 13 concurrent). One deteriorated after cycle 1 chemotherapy (further CT/RT cancelled). The median age was 66 (range 36-85). 51 were female, 36 were male. WHO PS at presentation: 0-36%, 1-43%, 2-18%, 3-2%. 70% had stage III disease. 44 patients had 2D RT planning; 42 patients had 3D; 3D planning increased over time. Only 15% received CCRT.

The expression of S100B protein in serum of patients with brain metastases from small-cell lung cancer and its clinical significance

“…Each year, ~15% of newly diagnosed cases of lung cancer are SCLC. The incidence of SCLC increases with age, and ~45% of patients are over the age of 70 ( 1 , 2 ). Therefore, early diagnosis of SCLC metastasis is an area of intense research ( 5 – 8 ).…”

“…The amount of S100B in serum is very low under physiological conditions. However, serum S100B protein can increase in response to increased blood-brain barrier permeability caused by damaged nerve cells or other pathological conditions ( 2 , 3 ). For example, increased levels of serum S100B are detectable in patients with Alzheimer's disease ( 4 ).…”

The S100 Protein Family as Players and Therapeutic Targets in Pulmonary Diseases

“…S100B is a nervous system-specific protein and is expressed in glial and Schwann cells [ 143 ]. Its levels can rise in response to increased blood-brain barrier permeability [ 143 , 144 ]. Increased expression of this protein is associated with brain metastases in patients with small cell lung cancer (SCLC) and may indicate poor prognosis as higher levels are linked with shorter survival time [ 145 ].…”